Data / Form D filings / PLx Pharma Inc.
PLx Pharma Inc.: Form D filings
PLx Pharma Inc., a pharmaceuticals company in Sparta, NJ, filed 9 Form D notices with the SEC between 2010 and 2020. The latest, on November 30, 2020, reports $18 million sold of a $18 million offering to 25 investors.
Find out what PLx Pharma Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 9 FISHERS LANE, SUITE E, Sparta, NJ, 07871
- Phone
- (973) 409-6541
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1497504
The full lists. Form D filings in New Jersey: 714 rows, $35.70, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 30, 2020 | New notice | $18,008,599 | $18,008,599 | $0 | 25 | Nov 18, 2020 | sec.gov |
| May 29, 2020 | New notice | $8,000,000 | $8,000,000 | $0 | 3 | May 15, 2020 | sec.gov |
| Mar 4, 2019 | New notice | $15,000,000 | $15,000,000 | $0 | 2 | Feb 20, 2019 | sec.gov |
| Jun 28, 2017 | New notice | $18,191,869 | $18,191,869 | $0 | 37 | Jun 14, 2017 | sec.gov |
| Jul 22, 2013 | New notice | $5,500,000 | $2,750,000 | $2,750,000 | 28 | Jul 12, 2013 | sec.gov |
| Feb 25, 2013 | New notice | $1,750,000 | $930,000 | $820,000 | 8 | Feb 13, 2013 | sec.gov |
| Apr 23, 2012 | New notice | $2,500,000 | $507,500 | $1,992,500 | 16 | Mar 30, 2012 | sec.gov |
| Nov 7, 2011 | Amendment | $3,000,000 | $2,740,000 | $260,000 | 34 | Jul 23, 2010 | sec.gov |
| Jul 30, 2010 | New notice | $2,500,000 | $1,070,000 | $1,430,000 | 23 | Jul 23, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Natasha Giordano | Executive Officer, Director | |
| Rita O'Connor | Executive Officer | |
| John W. Hadden II | Director | |
| Anthony J. Bartsh | Director | |
| Kirk J. Calhoun | Director | |
| Robert J. Casale | Director | |
| Gary J. Balkema | Director | |
| Michael J. Valentino | Executive Officer, Director |
Other pharmaceuticals companies in New Jersey that filed recently
- Grace Therapeutics, Inc. $10 million · Aug 11, 2026
Every Form D from the week of Nov 30, 2020 · All recent filings in New Jersey · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what PLx Pharma Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.